Integrated Wealth Concepts LLC Buys 52,662 Shares of Pfizer Inc. (NYSE:PFE)

Integrated Wealth Concepts LLC boosted its stake in Pfizer Inc. (NYSE:PFE) by 12.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 488,757 shares of the biopharmaceutical company’s stock after purchasing an additional 52,662 shares during the period. Integrated Wealth Concepts LLC’s holdings in Pfizer were worth $14,145,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Swiss National Bank increased its holdings in Pfizer by 0.6% during the third quarter. Swiss National Bank now owns 16,819,712 shares of the biopharmaceutical company’s stock valued at $486,762,000 after buying an additional 100,900 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Pfizer by 11.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company’s stock worth $3,766,366,000 after purchasing an additional 12,864,343 shares in the last quarter. Empowered Funds LLC raised its holdings in Pfizer by 80.9% in the 3rd quarter. Empowered Funds LLC now owns 508,256 shares of the biopharmaceutical company’s stock worth $14,709,000 after purchasing an additional 227,349 shares during the period. Addison Advisors LLC lifted its position in Pfizer by 394.2% during the third quarter. Addison Advisors LLC now owns 52,238 shares of the biopharmaceutical company’s stock valued at $1,512,000 after purchasing an additional 41,668 shares in the last quarter. Finally, KBC Group NV grew its holdings in Pfizer by 26.0% during the third quarter. KBC Group NV now owns 3,105,433 shares of the biopharmaceutical company’s stock valued at $89,872,000 after purchasing an additional 639,985 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 1.0 %

Shares of PFE stock opened at $25.56 on Wednesday. The company has a market cap of $144.85 billion, a PE ratio of 34.54, a price-to-earnings-growth ratio of 0.70 and a beta of 0.65. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The stock’s 50 day simple moving average is $27.68 and its two-hundred day simple moving average is $28.45. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm’s revenue was up 31.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.17) EPS. Research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, December 2nd. Stockholders of record on Friday, November 8th were given a dividend of $0.42 per share. The ex-dividend date was Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 6.57%. Pfizer’s dividend payout ratio (DPR) is 227.03%.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on PFE. Wolfe Research started coverage on Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Wednesday, October 23rd. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Citigroup started coverage on shares of Pfizer in a research note on Friday, October 25th. They set a “neutral” rating and a $30.00 target price for the company. Finally, Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $32.92.

Insider Activity

In related news, Director Scott Gottlieb bought 1,000 shares of the company’s stock in a transaction on Wednesday, October 30th. The shares were acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at $282,400. The trade was a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.